- Dr. Dario Marchetti
- Director, Biomarker Research Program, Houston Methodist Research Institute
Professor, Institute of Academic Medicine
Professor, Department of Molecular and Cellular Biology, Baylor College of Medicine
Member, Houston Methodist Cancer Center
Website | E-mail
Special Issue Introduction
The vast majority of cancer deaths (>94%) is due to the development of metastatic disease with a considerable fraction of patients experiencing metastatic relapse within five years from primary tumor resection, despite not having any detectable metastasis at that time. Circulating Tumor Cells (CTCs) are shed from primary/metastatic tumors, circulate in the peripheral vasculature, disseminate to distant tissues, extravasate by adapting to the new organ microenvironment, followed by tissue colonization generating metastasis. However, the complexities of the metastatic cascade in cancer patients and the elucidation of blood-based mechanisms underlying metastatic onset remain critical challenges.
Because CTC dissemination mostly occurs through the blood, and only a minute proportion of CTCs can generate metastasis (metastasis-competent CTCs), investigating the biology of CTCs for biomarker discovery is critically relevant and one of the most promising areas of modern oncology research. Equally - beyond CTCs - there have been also many advances to detect and interrogate blood-based, tumor-specific biomarkers such as circulating tumor DNA (ctDNA), circulating exosomes and extracellular vesicles, tumor-educated platelets (TEPs), circulating cell-free microRNA (cfRNA), proteins and metabolites. The use of these analytes to obtain valuable diagnostic information from a blood/body fluids rather than from a tissue biopsy sample is broadly referred as "liquid biopsy". The development and application of "liquid biopsy" testing in the cancer patient is a novel and powerful diagnostic concept to monitor cancer progression directly, in real time, and non-invasively. However, many scientific, procedural, and technical limitations must be overcome before the promise of "liquid biopsy" can be fulfilled and be successfully and consistently implemented in the clinics.
The objective of this Special Issue: “Application of Liquid Biopsy for Prognostic Status of Cancers and Drug Response" is to publish latest findings of liquid biopsy research and clinical application as prognostic indicator of therapy response.
Contributions outlining discoveries in this area and the development/application of liquid biopsy testing either in pre-clinical or clinical models will include Reviews and Commentaries updating upon the relevance of "liquid biopsy" and analytes validity in the prevention or treatment of different tumor types. This Special Issue will also include Research articles presenting innovative advances impacting the field on all aspects and components of liquid biopsy. All manuscript submissions will be given a fair evaluation by undergoing rigorous peer-review, and will be published if considered acceptable for scientific divulgation.
KeywordsLiquid Biopsy, Circulating Tumor Cells (CTCs), Circulating tumor DNA (ctDNA), Exosomes, Extracellular Vesicles (EVs), Circulating cell-free microRNA (cfRNA), Tumor-Educated Platelets (TEPs), Circulating Biomarkers.
Submission Deadline30 Sep 2019